INTRODUCTION

In light of recent articles that have reported no significant differences in oncological results between hemithyroidectomy and total thyroidectomy in patients with low- to intermediate-risk papillary thyroid carcinoma, the indications for hemithyroidectomy have been expanded [1,2]. However, controversy regarding central neck dissection persists, even in cases of hemithyroidectomy, given that occult nodal metastasis in the central compartment has been observed in approximately one-half of patients clinically diagnosed with N0 papillary carcinoma [3,4]. Some meta-analyses have investigated the effectiveness of prophylactic central neck dissection performed with total thyroidectomy [5-7], but not in patients undergoing hemithyroidectomy alone. The purpose of this study, therefore, was to evaluate the oncological effect of prophylactic central neck dissection performed during hemithyroidectomy in patients with low- to intermediate-risk papillary thyroid carcinoma.

MATERIALS AND METHODS

Literature search
The Embase and Medline database was searched on June 3, 2019 using the terms “papillary thyroid carcinoma,” “hemithyroidectomy,” “lobectomy,” and “central OR node.”
Inclusion criteria
Observational studies published as full-text articles in English were screened using following inclusion criteria: performance of central neck dissection was clearly stated; extent of thyroidectomy was clearly defined, and data regarding hemithyroidectomy were separately reported; recurrence was reported separately according to site (i.e., contralateral thyroid, and central and lateral compartments); and studies included patients with low to intermediate risk papillary thyroid carcinoma.

Data analysis
There were only two comparative studies; as such, all observational studies reporting oncological results after hemithyroidectomy—with or without central neck dissection—were searched and underwent proportional meta-analysis. The recurrence rate was calculated for the contralateral thyroid, and central and lateral compartments, separately. The proportional meta-analysis was performed using StatsDirect Ver. 3 (Cheshire, UK) and comprehensive meta-analysis (Biostat, Englewood, NJ, USA). Forest plots were constructed using Excel (Microsoft Corp., Redmond, WA, USA). Quality assessment of the included articles was performed using the risk of bias assessment tool for non-randomized studies (RoBNAS) and Review Manager ver. 5.3 (Cochrane Collaboration, Copenhagen, Denmark).

RESULTS
In total, 687 records were retrieved from the Embase database after removal of duplicates. Upon screening article titles, 621 irrelevant records were excluded. The abstract and full text of 66 records were screened, and 14 were included in the quantitative analysis. The articles published by Ebina et al. [8] and Liu et al. [9] reported follow-up data for patients who underwent hemithyroidectomy with central neck dissection, but were excluded. In the study by Ebina et al. [8], the extent of hemithyroidectomy was unclear and many subtotal thyroidectomies were included. In the study by Liu et al. [9], 62.8% of patients exhibited lateral neck metastasis, and it appeared that the researchers applied different indications from what is generally accepted (Fig. 1).

Table 1 summarizes the outcomes of the 14 studies that were ultimately included in the analysis [10-23]. Two studies investigated the impact of prophylactic central neck dissection in hemithyroidectomy using a comparative method [11,19]. Six investigations compared oncological results between total thyroidectomy and hemithyroidectomy in various subjects; however, only the data regarding hemithyroidectomy were included in the present study [10,12,13,20,21,23]. Others compared recurrence according to various factors among patients who underwent hemithyroidectomy [14-18,22]. The patients included were
| Study          | Institute                  | Year          | No. of cases | CND                      | Inclusion criteria                                                                 | Demographic finding                                                                 | Follow-up period | Outcome analysis                                                                 | Recurrence                                                                 |
|----------------|---------------------------|---------------|--------------|--------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Choi et al.    | Yonsei University, Korea | 1978–2011     | 974          | Routine CND              | 1–4 cm, DTC (PTC, 97.5%; FTC, 2.5%)                                                | Tumor size: 1.6 cm, multiple: 15.6%, bilateral nodule: 5.3%, ETE: 46.3%, pN1a: 32.3% | 57.3±58.1 mo     | Comparison of oncologic result after TT vs. lobectomy in 1–4 cm size DTC          | Contralateral lobe: 87, operation bed: 1, central node: 0, lateral node: 1 |
| Hyun et al.    | Asan Medical Center, Korea| 2001–2009     | 105 (152 before exclusion of cases with completion thyroidectomy) | CND+: 42 (65 before excluding completion) CDN–: 63 (87 before excluding completion) | PTMC ≤ 1 cm, no clinically apparent ETE, cN0, M0 from ENT department               | Tumor size: 1 cm, multiple: 5%, ETE: 37%, N1a: 29% > 1 cm: 10%, multiple: 10%, ETE: 43%, N1a: unknown | 51.3±25.89 mo    | Oncologic outcome according to CND in lobectomy cases                            | Contralateral lobe: 1, lobe only: 5, central lobe: 2, contralateral lobe+central+lateral: 1, central+lateral: 1 |
| Kuba et al.    | Nagasaki University, Japan| 1994–2008     | 120          | Routine CND; 30 cases without preoperative diagnosis of PTC didn't do CND. | 1–5 cm Thyroid cancer, cN0, cM0                                                  | Tumor size: 1.7 (1.2–2.2), multiple: 21.7%, ETE: 39.2%, pN1a: 40.8%                | 112 mo           | Oncologic outcome between TT vs. lobectomy                                       | Thyroid and lymph node: 5, lymph node: 4 (central and lateral compartment is not specified) |
| Kwon et al.    | Asan Medical Center, Korea| 1998–2007     | 688          | Routine CND              | PTMC only. N1b, M1 is excluded. Lobectomy and TT were one-to-one matched according to factors from internal medicine dept. | Before one-to-one matching (n = 755), tumor size: 0.6 (0.5–0.8), ETE: 36%, multiple: 10%, N1a: 28% | 8.5 yr          | Oncologic outcome between TT vs. lobectomy in PTMC                                | Contralateral lobe: 22, central node: 0, lateral node: 4                      |
| Lee et al.     | Yonsei University, Korea | 1986–2001     | 281          | Routine CND              | PTMC only; exclusion: multifocal PTC, definite ETE, cN+, RT history                | Tumor size: 0.68±0.27, 0.56±0.23, 9.3% and 8.8%; ETE: 51.2% and 23.9% for pN1a and pN0, respectively | 12.7 yr (4–24 yr) | Oncologic outcome between pN1a vs. pN0 in PTMC                                   | Contralateral lobe: 18, central lobe: 1, central node: 2                      |
| Li et al.      | Tianjin Medical University, China | 2006–2007     | 135          | Routine CND              | PTMC, no ETE, cN0, ipsilateral disease                                             | NC                                                                                   | 40.0±6.55 mo     | Oncologic outcome between solitary vs. multiple PTC                               | Contralateral lobe: 6                                                        |
| Matsuzu et al. | Yokohama City University, Japan | 1986–1995     | 1,088        | Routine CND and LND; CND only: 60, CND+LND: 898, no ND: 130 | Consecutive cases of lobectomy for PTC with more than 5-year follow-up             | Tumor size: ≤ 1 cm: 14.3%, 1–2 cm: 33.7%, 2–4 cm: 41.9%, > 4 cm: 10%; ETE: 7.7%, multiple: 14.6%, cN+: 6.3%, pN+: 86.3% | 17.6 yr         | Long-term follow-up data of lobectomy                                             | Contralateral lobe: 52, lymph node: 92, distant: 35 (central and lateral compartment is not specified) |

(Continued to the next page)
| Study                  | Institute                     | Year        | No. of cases | CND  | Inclusion criteria                                      | Demographic finding                          | Follow-up period | Outcome analysis                                      | Recurrence                                    |
|-----------------------|-------------------------------|-------------|--------------|------|---------------------------------------------------------|-----------------------------------------------|------------------|------------------------------------------------------|-----------------------------------------------|
| Ahn et al.            | Korea                         | 2004–2016   | 734          | Not performed | PTC confined to one thyroid, cN0, M0                     | Tumor size: ≤1 cm: 90.6%, 1–2 cm: 8.6%, > 2 cm: 0.8%; ETE: 25.9%, multiple: 13.2% | 197              | Oncologic result after lobectomy without CND         | Contralateral lobe: 17, contralateral lobe + central + lateral node: 1, contralateral lobe + central + lateral node: 2, central node: 1, central + lateral node: 2 |
| Park et al.           | Korea University, Korea       | 2004–2016   | 734          | Routine CND  | Solitary intra-thyroidal classic PTC ≤1 cm, from GS dept | Tumor size: 0.86±0.45; ETE: 43.1%, multiple: 8.6%, pN1a: 54.9% | 107              | Prolonged value of serum TSH level in lobectomy      | Central node: 1, lateral node: 36, lateral node + distant meta: 3, distant meta: 2 (no description about contralateral lobe recurrence) |
| Son et al.            | Catholic University of Daegu, Korea | 2005–2015   | 537          | CND+: 399    | PTC <1 cm, pN0, M0, follow-up >24 months               | Tumor size: 0.45 (0.1–1.0), ETE: 5.8%, multiple: 7.3% | 56               | Oncologic outcome according to CND in lobectomy cases | Contralateral lobe: 9, central node: 4, lateral node: 3, lateral node: 4 |
| Song et al.           | Asan Medical Center, Korea     | 1998–2007   | 381          | Routine CND  | 1 cm ≤Tumor size <4 cm PTC, cN1b excluded              | 1–2 cm: 326, 2–4 cm: 55; ETE: 42.5%, multiple: 11.0%, N1a: 36.5% | 9.8              | Oncologic outcome according to TT vs. lobectomy with propensity score matching of TT group | Contralateral lobe: 11, contralateral lobe + lateral node: 7, lateral node: 3, operation bed: 2, distant meta: 1 |
| Vaisman et al.        | Memorial Sloan-Kettering Cancer Center, USA | NC        | 72           | Not performed; CND: 1, LND: 1 included | <4 cm, cN0, normal contra-lateral lobe in USG         | 1 Poorly differentiated ca, 2 follicular ca, 3 Hurthle cell ca included | 6.8              | Oncologic outcome between TT vs. lobectomy           | Contralateral lobe: 3                          |
| Vaisman et al.        | Universidade Federal do Rio de Janeiro, Brazil | NC        | 70           | No prophylactic ND (44 CND−/19 CND+)                   | DTC >1 cm with lobectomy                        | Tumor size: 2.0 (0.2–6.0); 14 follicular ca included, multiple: 15.7%, N1a: 7.1% | 12               | Oncologic outcome with lobectomy in DTC              | Contralateral lobe: 4, central node: 1         |
| Xue et al.            | The First Hospital of Jilin University, China | 2005–2006   | 57           | Routine CND  | Unilateral multifocal PTMC                              | Tumor size: >5 mm: 29.82%, ≤5 mm: 70.18%, Foci number: >3: 15.79%, ≤3: 84.21%, pN1a: 59.65% | 126±5 mo         | Oncologic outcome of multifocal PTMC according to TT vs. lobectomy | Contralateral lobe: 14, central node: 1         |

CND, central neck dissection; DTC, differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; ETE, extrathyroidal extension; TT, Total thyroidectomy; PTMC, papillary thyroid microcarcinoma; RT, radiation therapy; NC, Not clarified; LND, lateral neck dissection; TSH, thyroid stimulating hormone; USG, ultrasonography.
mostly those with a tumor size < 4 cm and no clinical preoperative lymph node metastasis. The rates of developing new carcinoma in the contralateral thyroid, lymph node metastasis in the central compartment, and lymph node metastasis in the lateral compartment were calculated separately. In studies in which routine central neck dissection was performed, the rate of occult metastasis in the central compartment was found to range from 28.0% to 59.65%.

In the quality assessment according to the RoBNAS criteria, most studies were found to be free of problems. Kwon et al. [13] did not report oncological results from all patients; results were only reported for 688 of the 755 patients used for case-control matching Vaisman et al. [21,22] included cases other than papillary carcinoma in both studies. Xue et al. [23] only selected cases of multifocal papillary thyroid carcinoma. Therefore, these four studies were classified as having a high risk of bias in participant selection. Vaisman et al. [22] did not clearly describe the number of patients who underwent central neck dissection, although the authors reported that they did not routinely perform prophylactic central neck dissection; therefore, their study was classified as having a high risk of bias in confounding variables. Studies by Kuba et al. [12] and Matsuzu et al. [16] did not report lymph node metastasis in the central and lateral compartments separately. Park et al. [18] did not report recurrence in the contralateral thyroid and, in one study by Vaisman et al. [22], the follow-up period was too short (12 months; range, 3–28 months), making it difficult to calculate the true recurrence rate. Thus, these studies were classified as having a high risk for bias in incomplete outcome data (Fig. 2).

In the proportional meta-analysis, central compartment recurrence occurred in 0% to 1.75% of cases, with a mean of 0.17% when prophylactic central neck dissection was performed. When it was not performed, the recurrence rate was found to be 0% to 6.4%, with a mean of 1.78%. A between-group comparison according to whether prophylactic central neck dissection was performed yielded a significant difference ($P=0.018$) (Fig. 3A). Lateral compartment recurrence demonstrated no difference according to whether prophylactic central neck dissection was performed; the recurrence rate ranged from 0% to 3.72%, with a mean of 1.31% (Fig. 3B). Carcinoma in the contralateral thyroid was observed in 2.17% to 24.6% of cases, with a mean of 5.44% in total; no significant difference was found according to whether central neck dissection was performed (Fig. 3C).

### DISCUSSION

Although many studies have investigated the issue, controversy continues regarding the value of prophylactic central neck dissection. In the American Thyroid Association (ATA) guidelines published in 2016, prophylactic central neck dissection was not recommended for T1- or T2-differentiated thyroid cancers [24]. The authors of the guideline stated that prophylactic central neck dissection can identify a substantial number of pN1 patients; however, the direct effect of this procedure is small. Another problem with central neck dissection during total thyroidectomy is that morbidity can be excessively high when an inexperienced surgeon is operating.

Some meta-analyses have analyzed the effect of central neck dissection in patients undergoing total thyroidectomy. A common finding of those studies is that prophylactic central neck dissection reduced locoregional recurrence from 4.59%–8.6% to 2.52%–5.9% [5-7,25]. This change in locoregional recurrence was due to decreased recurrence in the central compartment,
Fig. 3. Proportional analysis of recurrence after lobectomy with or without central neck dissection. Comparisons of recurrence in the central compartment (A), recurrence in the lateral compartment (B). CI, confidence interval; CND, central neck dissection. (Continued to the next page)
but not in the lateral compartment [7]. However, radioactive iodine therapy and thyroid-stimulating hormone (TSH) suppression can be a confounding factor for this reduction in regional recurrence rates. When a tumor is pathologically diagnosed as N1 by central neck dissection, radioactive iodine therapy may be used with a higher dose and more stringent TSH suppression will be applied. Therefore, although there is no clear evidence that the addition of radioactive iodine therapy or TSH suppression reduces recurrence, postoperative treatment could be a confounding variable. In contrast, morbidity is significantly increased by central neck dissection in patients undergoing total thyroidectomy. According to previous meta-analyses, the risk for recurrent laryngeal nerve paralysis did not change according to whether central neck dissection was performed. However, central neck dissection significantly increased the risk of transient and permanent hypocalcemia [5-7]. Therefore, balancing the risks and benefits of central neck dissection is an important consideration in patients undergoing total thyroidectomy.

Until the revised ATA guideline was published in 2016, total thyroidectomy was regarded as the optimal surgical procedure in most cases of papillary thyroid carcinoma. However, recent reports describing outcomes in patients receiving active surveillance for papillary microcarcinoma have significantly changed surgeons’ approach to thyroid surgery [26,27], and hemithyroidectomy—as a more conservative procedure—is now regarded as optimal in many instances, even in the revised ATA guidelines [24]. Nevertheless no meta-analyses have yet investigated the effects of central neck dissection in hemithyroidectomy. In addition, radioactive iodine therapy is not possible after hemithyroidectomy, and TSH suppression is not applied or only minimally applied. Therefore, we believed that it would be possible to substantiate the benefit of prophylactic central neck dissection in hemithyroidectomy, while excluding other confounding factors.

Because hypocalcemia rarely occurs after hemithyroidectomy, this meta-analysis only analyzed clinical outcomes involving recurrence. In total, recurrence in the contralateral thyroid lobe was observed in 5.4% of patients, without a significant difference according to whether central neck dissection was performed, as expected. Recurrence in the lateral compartment was also not affected by central neck dissection, with an average recurrence rate of 1.31%. However, the recurrence rate in the central compartment was significantly lower in patients who underwent prophylactic central neck dissection (0.17% vs. 1.78%). This result is consistent with a previous meta-analysis investigating total thyroidectomy, and it clearly demonstrates the benefit of prophylactic central neck dissection without confounding factors.

Although the benefit may be very small, we believe it is mean-
No potential conflict of interest relevant to this article was reported.

ORCID
Soon-Hyun Ahn https://orcid.org/0000-0002-0759-6850
Won Sik Kim https://orcid.org/0000-0002-9871-4655

AUTHOR CONTRIBUTIONS
Conceptualization: SHA. Data curation: all authors. Writing - original draft: SHA. Writing - review & editing: all authors.

REFERENCES
1. Mendelsohn AH, Elashoff DA, Abemayer E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010 Nov;136(11):1055-61.
2. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011 May;33(5):645-9.
3. Koo BS, Choi EC, Yoon YH, Kim DH, Kim EH, Lim YC. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg. 2009 May;249(5):840-4.
4. Roh JL, Kim JM, Park CI. Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Ann Surg Oncol. 2011 Aug;18(8):2245-50.
5. Hughes DT, Rosen JE, Evans DB, Grubbs E, Wang TS, Solorzano CC. Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence. Ann Surg Oncol. 2018 Sep;25(9):2526-34.
6. Chen L, Wu YH, Lee CH, Chen HA, Loh EW, Tam KW. Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis. World J Surg. 2018 Sep;42(9):2846-57.
7. Zhao WJ, Luo H, Zhou YM, Dai WY, Zhu JQ. Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for clinical-stage cN0 papillary thyroid carcinoma: an updated meta-analysis. Eur J Surg Oncol. 2017 Nov;43(11):1989-2000.
8. Ebina A, Sugitani I, Fujimoto Y, Yamada K. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients? Surgery. 2014 Dec;156(6):1579-88.
9. Liu J, Zhang Z, Huang H, Xu S, Liu Y, Liu S, et al. Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: a single-institution matched-pair analysis. Oral Oncol. 2019 Mar;90:17-22.
10. Choi JB, Lee SG, Kim MJ, Kim TH, Ban EJ, Lee CR, et al. Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy. Head Neck. 2019 Jan;41(1):56-63.
11. Hyun SM, Song HY, Kim SY, Nam SY, Roh JL, Han MW, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. Ann Surg Oncol. 2012 Feb;19(2):591-6.
12. Kuba S, Yamanouchi K, Hayashida N, Maeda S, Asada T, Sakimoto C, et al. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: comparative analysis after propensity score matching: a multicenter study. Int J Surg. 2017 Feb;38:143-8.
13. Kwon H, Jeon MJ, Kim WG, Park S, Kim M, Song DE, et al. A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a prospective individual risk factor-matched cohort study. Eur J Endocrinol. 2017 Apr;176(4):371-8.
14. Lee CR, Son H, Lee S, Kang SW, Jeong JJ, Nam KH, et al. Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma: do involved lymph nodes mandate completion thyroidectomy? World J Surg. 2014 Apr;38(4):872-7.
15. Li X, Zhao C, Hu D, Yu Y, Gao J, Zhao W, et al. Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma. Oncol Lett. 2013 Apr;5(4):1412-6.
16. Matsuura K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014 Jan;38(1):68-79.
17. Park YM, Lee DY, Oh KH, Cho JG, Baek SK, Kwon SY, et al. Clinical implications of pathologic factors after thyroid lobectomy in patients with papillary thyroid carcinoma. Oral Oncol. 2017 Dec;75:1-5.
18. Park JH, Lee YM, Lee YH, Hong SJ, Yoon JH. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma. J Surg Oncol. 2018 Sep;118(3):390-6.
19. Son HJ, Kim JK, Jung YD, Jung GH, Seo YT, Kim DS, et al. Comparison of outcomes between hemithyroidectomy alone and hemithyroidectomy with elective unilateral central neck dissection in patients with papillary thyroid microcarcinoma. Head Neck. 2018 Nov;40(11):2449-54.
20. Song E, Han M, Oh HS, Kim WW, Jeon MJ, Lee YM, et al. Lobectomy is feasible for 1-4 cm papillary thyroid carcinomas: a 10-year propensity score matched-pair analysis on recurrence. Thyroid. 2019 Jan;29(1):64-70.
21. Vaisman F, Shaha A, Fish S, Michael Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011 Jul;75(1):112-9.
22. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, da Cruz MD, Dias F, et al. Thyroid lobectomy is associated with excellent clinical outcomes in properly selected differentiated thyroid cancer patients with primary tumors greater than 1 cm. J Thyroid Res. 2013;2013:398194.
23. Xue S, Wang P, Liu J, Chen G. Total thyroidectomy may be more reasonable as initial surgery in unilateral multifocal papillary thyroid microcarcinoma: a single-center experience. World J Surg Oncol.
24. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.

25. Lang BH, Ng SH, Lau LL, Cowling BJ, Wong KP, Wan KY. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid. 2013 Sep;23(9):1087-98.

26. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014 Jan; 24(1):27-34.

27. Sugitani I, Fujimoto Y, Yamada K. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg. 2014 Mar;38(3):673-8.